XBIOTECH INC. (NASDAQ:XBIT) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
The annual meeting of the stockholders of XBiotech Inc. (the
Company) was held on June 19, 2017. The matters that were voted
upon at the meeting, and the number of votes cast for and
against, as well as the number of abstentions and broker
non-votes as to each such matter are set forth below.
Stockholders voted in accordance with the Board of Directors
recommendations on each matter and voted to (1) elect four
nominees for director; and (2) ratify the selection by the Audit
Committee of the Board of Directors of Ernst Young LLP as the
Companys independent registered public accounting firm for the
fiscal year ending 2017.
Proposal #1 Election of four members of the Board
of Directors
| For | Abstain | Broker Non-Votes | |
| John Simard | 11,425,514 | 9,820 | 1,942,756 |
| Dr. Fabrizio Bonanni | 11,403,204 | 32,130 | 1,942,756 |
| W. Thorpe McKenzie | 11,162,955 | 272,379 | 1,942,756 |
| Dr. Daniel Vasella | 11,404,451 | 30,883 | 1,942,756 |
Proposal #2 Ratification of the selection of Ernst
Young LLP as the Companys independent registered public
accounting firm for the fiscal year ending 2017
| For | Against | Abstain | Broker Non-Votes |
| 13,224,828 | 65,355 | 87,907 |
About XBIOTECH INC. (NASDAQ:XBIT)
XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. The Company’s therapeutic antibody Xilonix is being evaluated as a monotherapy to treat advanced stages of colorectal cancer. Xilonix neutralizes a pro-inflammatory protein produced by leukocytes and other cells, interleukin-1 alpha (IL-1a). The Company completed a Phase I and II clinical trial for MABp1 as a treatment for cancer at MD Anderson Cancer Center. The Company is also investigating MABp1 in clinical trials for other indications, including vascular disease, type II diabetes, acne and psoriasis.
